Overview of Oflox-Tz

Quick Facts

Property	Description
Active Ingredient	Ofloxacin and Tinidazole
Form	Tablet and Oral Suspension
Pharmacological Class	Fluoroquinolone and Nitroimidazole Antibiotic, Antiprotozoal Agent
Common Use Type	Treatment of Mixed Bacterial and Protozoal Infections
Origin	Synthetic

What is Oflox-Tz and Why is it a Fixed-Dose Combination?

Oflox-Tz is a popular trade name for the Fixed-Dose Combination (FDC) medicine composed of two distinct, synthetic active ingredients: Ofloxacin and Tinidazole. This prescription-only oral preparation is intended for systemic treatment, delivering both antimicrobial agents simultaneously in a single dose unit, such as an oral tablet or a liquid oral suspension. This FDC design is recognized across medical guidelines for its broad-spectrum applicability, supported by pharmacological evidence regarding the efficacy of combination regimens. Other products sharing this identical composition include brands such as Oflomac TZ and Oflotas-tz, all delivering the same dual therapeutic components.

Ofloxacin and Tinidazole: The Dual Pharmacological Class

This formulation is classified as a dual Antibiotic and Antiprotozoal Agent due to the complementary roles of its components. Ofloxacin is specifically categorized as a Fluoroquinolone antibiotic, an agent recognized for targeting aerobic bacteria. Tinidazole is a distinguished Nitroimidazole antimicrobial, acting as both an antibiotic and an antiprotozoal agent, with established clinical recognition for its activity against anaerobes and certain protozoal infections. The combined pharmacological approach is commonly utilized in scenarios where the infection source is suspected to involve a mix of aerobic bacteria and low-oxygen thriving microorganisms.

General Purpose of this Systemic Antimicrobial Agent

The general purpose of this systemic antimicrobial agent is to achieve the comprehensive elimination of pathogens in mixed infections, where both types of susceptible microorganisms—aerobic bacteria and anaerobic bacteria or protozoa—may be present. The combination utilizes the distinct actions of the two active ingredients to suppress or eradicate a wider range of infectious agents, thereby ensuring a robust therapeutic approach aimed at resolving complex microbial challenges within the body.

Regulatory References

What side effects are possible with Oflox-Tz?

Possible Side Effects and Safety Information

The safety profile of Oflox-Tz, a fixed-dose combination of Ofloxacin (a fluoroquinolone) and Tinidazole (a nitroimidazole), is governed by the documented risks of both active ingredients as classified by regulatory authorities.

Official Adverse Reaction Scope

Adverse reactions are formally organized into System-Organ Classes. Common reactions (ge 1/100 to <1/10) include gastrointestinal disturbances such as nausea, vomiting, and diarrhea, along with headache and a metallic taste (primarily from Tinidazole). Uncommon reactions (ge 1/1,000 to <1/100) may include skin rash and insomnia. Rare reactions (ge 1/10,000 to <1/1,000) documented in labeling include tendon disorders, confusion, and photosensitivity.

Documented Serious Adverse Reactions

The most significant risks, explicitly noted as serious in regulatory documents, pertain to the Ofloxacin component. These include the potential for Tendon Rupture (which can occur during or up to several months after treatment cessation) and the occurrence of potentially irreversible Peripheral Neuropathy. The product label also notes the risk of severe reactions such as Anaphylaxis, Pseudomembranous Colitis, and Convulsions. Tinidazole contributes a notable restriction: the disulfiram-like reaction when taken with alcohol.

Population-Specific Safety Considerations

Regulatory safety statements specify caution for certain populations. Older adults have a documented increased risk of tendon disorders. Use is restricted or contraindicated in pediatrics due to the risk of arthropathy. Individuals with a history of epilepsy, QTc interval prolongation, or pre-existing tendon disorders related to fluoroquinolones are subject to formal safety limitations. These classifications strictly reflect how government agencies organize and communicate the medicine’s risk profile.

Overdose and Emergency Response

The section on overdosage details the officially documented manifestations and required emergency procedures for Ofloxacin and Tinidazole. Overexposure to the Ofloxacin component is associated with severe Central Nervous System (CNS) effects. Documented presentations of overdose include convulsions (seizures), toxic psychosis, tremors, restlessness, agitation, confusion, hallucinations, and increased intracranial pressure. Additionally, there is a risk of reversible renal toxicity and the potential for crystalluria, which necessitates careful clinical monitoring. The official regulatory labeling for Tinidazole states that no reported overdoses in humans are available.

Upon any suspected overdosage, regulators mandate that a patient seek immediate medical attention and contact a Poison Control Center or emergency room at once. Urgent medical help is specifically required if the patient exhibits severe signs such as collapse, seizure, trouble breathing, or inability to be awakened.

As no specific antidote is known for either component, treatment is symptomatic and supportive. Officially described supportive measures include the potential use of gastric lavage and ensuring adequate hydration to manage the risk of crystalluria. Monitoring of renal function and observation of the patient are required. The elimination profile is constrained by the fact that Ofloxacin is only minimally removed by hemodialysis, while Tinidazole is easily dialyzable.

Therapeutic Uses of Oflox-Tz

What Oflox-Tz Treats: Main Uses and Benefits

Oflox-Tz is a combination medicine relevant for managing a range of mixed infections involving both susceptible bacteria and protozoal organisms. This dual-action approach is applied across domains where additional symptomatic support is needed, contributing to easing the overall symptom burden. One of the components, Tinidazole, is a recognized antiprotozoal and is an anaerobic antibacterial agent.

The medicine is commonly used across conditions presenting with acute episodes, such as infectious diarrhea, dysentery, giardiasis, amebiasis, and certain genitourinary infections. It helps address symptom clusters that may become intense or disruptive, such as abdominal discomfort, pain, and heightened physiological activity, which create noticeable physiological strain.

“It is commonly used when short-term symptomatic assistance is needed for conditions marked by increased physiological stress.”

Quick Fact: Focus on Acute Discomfort

Oflox-Tz is applied in clinical settings that involve acute or unstable symptom patterns, often during phases where the patient experiences heightened discomfort. The key benefit offers symptomatic relief that helps patients cope more steadily with difficult episodes, and assists with supporting functional stability.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Oflox-Tz

Contraindicated Populations

Use of Oflox-Tz is prohibited (contraindicated) for specific patient groups due to serious safety risks, including:

Patients with known hypersensitivity or allergy to Ofloxacin, Ornidazole, any other quinolone, or nitroimidazole antibiotic.
Individuals with a history of tendinitis or tendon rupture associated with prior quinolone use.
Patients with a known history of Myasthenia Gravis or epilepsy (seizure disorder).
Children and growing adolescents (under 18 years of age) due to the risk of joint cartilage damage.
Pregnant and breastfeeding women.

Restricted or Cautionary Use

Special caution, or a reduced dosage, is required for patients with the following conditions:

Renal impairment (kidney disease).
Hepatic impairment (liver disease or cirrhosis).
Elderly patients (over 60 years of age), who face an increased risk of tendon damage, particularly when also taking corticosteroids or after an organ transplant (kidney, heart, or lung).
Patients with a history of central nervous system (CNS) disorders, psychiatric conditions, or conditions leading to a lowered seizure threshold.

This medication is only recommended for use in the adult population when no alternative treatment options are available and when potential benefits outweigh the risks associated with the fluoroquinolone class of antibiotics.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for the combination of Ofloxacin and Tinidazole outlines specific interaction constraints that must be observed.

Contraindicated Combinations and Restrictions

Co-administration with Tizanidine is contraindicated, as Ofloxacin significantly increases Tizanidine plasma concentrations. The consumption of alcohol or ethanol-containing products is strictly restricted and must be avoided during and for at least 72 hours after the completion of Tinidazole therapy due to the documented risk of a severe disulfiram-like reaction.

Pharmacokinetic and Pharmacodynamic Interactions

The Ofloxacin component reduces the clearance of Theophylline, which may result in an increased plasma concentration of Theophylline. The co-administration of Warfarin and other oral Coumarin anticoagulants with Tinidazole may potentiate their effect, increasing the documented risk of bleeding. Certain anti-diabetic agents combined with Ofloxacin carry a risk of severe hypoglycemia. Combining Ofloxacin with Corticosteroids is associated with an increased, officially labeled risk of tendinitis and tendon rupture.

Administration Timing Requirements

Absorption-reducing agents such as Antacids, Sucralfate, Didanosine (buffered), and supplements containing Iron or other polyvalent cations must be administered at least 2 hours before or 2 hours after the dose of the Ofloxacin component to prevent a reduction in systemic exposure.

Population-Specific Notes

The increased susceptibility to the interaction between Ofloxacin and Corticosteroids (tendon disorders) is specifically noted in elderly patients (over 60 years).

Mechanism of Action

How Oflox-Tz Works

The action of Oflox-Tz results from two distinct mechanisms that target different microbial environments.

Inhibiting DNA Maintenance in Aerobic Bacteria

This domain focuses on the Ofloxacin component, which selectively attacks crucial enzyme systems in aerobic and facultative anaerobic bacteria. Ofloxacin acts as an inhibitor of DNA Gyrase and Topoisomerase IV, stabilizing the toxic enzyme-DNA complex to induce lethal double-strand DNA breaks. This molecular damage triggers the bacterial SOS response, leading to the pathogen's programmed cell death, which contributes to the reduction of the systemic microbial load.

Generating Cytotoxic Free Radicals in Anaerobic Organisms

This domain involves Tinidazole, a prodrug that is only activated by the low-oxygen conditions and specific electron-transport proteins found in anaerobic bacteria and protozoa. This reductive activation generates highly reactive nitro-free radical intermediates that cause non-specific destruction to the pathogen’s DNA and cellular macromolecules. This chemical action prevents the synthesis of nucleic acids, resulting in the death of susceptible anaerobic and protozoal populations.

Orthogonal Targeting for Broad Mechanistic Coverage

The combination employs orthogonal targeting, where Ofloxacin addresses aerobic microbial processes while Tinidazole addresses anaerobic processes. This simultaneous, dual-mode attack engages two fundamentally different pathways, which contributes to the elimination of susceptible pathogens across diverse physiological environments within the body.

Dosage and Administration Information

How to use Oflox-Tz: Administration Guidelines

The following instructions summarize the usage principles for the Ofloxacin and Tinidazole fixed-dose combination (FDC) as stipulated in prescribing information.

Administration Requirements

Usage Entity	Guideline
Route of Administration	Primarily the Oral route (tablet/caplet). The component drugs may be administered separately via the intravenous (IV) route in severe, non-oral cases, with a planned switch to oral as appropriate.
Standard Dosing Schedule	The adult dose typically ranges from 200 mg Ofloxacin / 600 mg Tinidazole daily to 400 mg Ofloxacin / 1200 mg Tinidazole twice daily. A single-dose regimen of 400 mg Ofloxacin/1200 mg Tinidazole is utilized for certain uncomplicated infections.
Dosing Frequency	The dose is taken either Once Daily or Twice Daily (b.i.d.) at approximately equal intervals.
Intake Timing	The oral dose must be taken during or immediately after a meal.
Special Conditions	Tablets must be swallowed whole with an adequate amount of water. Co-administration must be avoided with dairy products (milk, yogurt) or mineral-fortified fruit juices, and patients should maintain plentiful fluid intake throughout the course of treatment.

Population-Specific Dosing Rules

Prescribing labeling specifies dose modifications for certain populations:

Pediatric Use: The FDC product is not recommended for use in individuals below the age of 18 years.
Renal Impairment: Dosing requires adjustment based on the patient's creatinine clearance (CrCl). For severe impairment (CrCl < 20 ml/min), a reduced maintenance dose, typically 100 mg Ofloxacin/300 mg Tinidazole per day, is mandated.

Procedural Protocol

The protocol for use requires the oral dose to be taken whole, accompanied by food or immediately after a meal, while strictly avoiding interactions with dairy or mineral-fortified fluids. The total duration of use is not fixed and is determined by the site, type, and severity of the diagnosed infection, ensuring flexible application of the systemic therapy.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Oflox-Tz

Evidence for Use in Mixed Diarrheal Infections and Dysentery

This medicine was studied in research examining acute conditions like diarrhea and dysentery where the involvement of both aerobic bacteria and low-oxygen thriving organisms (anaerobes or protozoa) was suspected. The evidence base includes short-term randomized controlled trials (RCTs) and observational cohorts. Researchers designed these studies to measure microbiological eradication (confirming the clearance of identified infectious organisms) and clinical cure rates (tracking the return to stable stool frequency and consistency).

Studies reported measurements of how symptoms evolved and pathogen clearance over the defined study time intervals. Data show patterns related to outcomes that were short-term and based on populations in specific regional settings, and the evidence quality varies across studies. The certainty regarding the fixed-dose combination structure remains low. There is limited information for long-term outcomes such as recurrence rates.

Evidence for Use in Protozoal Infections

The research examined the use of this combination in conditions such as giardiasis and amebiasis. The evidence strongly involves studies on the Tinidazole component evaluated in the context of protozoal infections. Systematic reviews and clinical trials for Tinidazole were evaluated in research exploring short-term symptom changes. Outcomes studied included parasitological cure rates and patient-reported outcomes describing perceived discomfort.

Studies examining the nitroimidazole component reported consistent patterns of activity. A key uncertainty is that few dedicated FDC trials are available to fully assess the specific contribution of the Ofloxacin component when the infection is confirmed to be primarily protozoal. The research provides context but not individual predictions, and data for certain groups remain insufficient.

Understanding Research Gaps and Uncertainties

The evidence base highlights key areas where more research is needed. A major gap is the lack of large, independent, international randomized controlled trials (RCTs) specifically designed to explore whether the fixed-dose combination results in patterns of response distinct from using the two active ingredients separately or sequentially. Another uncertainty is that evidence quality varies across studies, and many findings were mixed or based on small sample sizes.

Key Studies & References

National Institutes of Health (NIH) StatPearls: Fluoroquinolones and Nitroimidazoles Pharmacological Classification

Frequently Asked Questions (FAQ)

Common questions about Oflox-Tz (FAQ)

Q: Is Oflox-Tz safe to take if I drink coffee?

A: Official information indicates that the Ofloxacin component, a fluoroquinolone, may potentially affect how your body processes caffeine. This can sometimes lead to an increase in the effects of caffeine, which might include feeling nervous, having trouble sleeping, or experiencing a rapid heartbeat. A general precaution noted in official information is monitoring and potentially limiting caffeine intake during treatment.

Q: Are there any specific foods to avoid while taking Oflox-Tz?

A: The official instructions indicate that co-administration with dairy products (such as milk or yogurt) or mineral-fortified fruit juices must be avoided. Beyond these specific items, the oral dose is stipulated to be taken during or immediately after a meal in the official instructions.

Q: Is it normal to feel a metallic taste in my mouth while on Oflox-Tz?

A: Yes, a metallic or bitter taste in the mouth is described in regulatory documents as a common adverse reaction associated with the medicine. This is primarily attributed to the Tinidazole component. Experiencing this taste is a known, documented effect of the treatment.

Q: What happens if I take Oflox-Tz and alcohol together?

A: Official warnings state that the consumption of alcohol or ethanol-containing products is strictly restricted during therapy and for at least 72 hours after completion. This combination can cause a severe reaction, described as a disulfiram-like reaction, which may involve symptoms such as flushing, vomiting, stomach cramps, headaches, and sweating.

Q: Does Oflox-Tz interact with common pain relievers like ibuprofen?

A: Regulatory information indicates that combining the Ofloxacin component (a fluoroquinolone) with certain nonsteroidal anti-inflammatory drugs (NSAIDs), which includes medicines like ibuprofen, requires caution. Some official labels describe a potential increased risk of Central Nervous System (CNS) stimulation or seizures when these drugs are used together.

Q: Why is hydration often recommended when taking drugs like Oflox-Tz?

A: The Ofloxacin component is primarily eliminated from the body through the kidneys. Maintaining plentiful fluid intake is a general requirement of administration mentioned in official guidelines to facilitate the elimination process.

Q: Can Oflox-Tz make skin issues worse?

A: Official safety documents list the potential for skin-related adverse reactions. These include an uncommon skin rash and a rare risk of photosensitivity, which means the skin may react more strongly to sunlight. Patients should be aware of these documented effects.

Q: What does 'combination therapy' mean when talking about Oflox-Tz?

A: When used for Oflox-Tz, combination therapy refers to the medicine being a Fixed-Dose Combination (FDC). This means the single dose unit contains two different active ingredients, Ofloxacin and Tinidazole, to address mixed infections that may involve both aerobic bacteria and anaerobic organisms or protozoa.

Q: Does Oflox-Tz interact with herbal supplements?

A: Official regulatory guidance indicates that the use of all over-the-counter products, including herbal and dietary supplements, may carry the potential for unforeseen interactions and is an area requiring caution. These products are generally not listed as known interactions in official documentation.

Q: Why is the full name of the drug sometimes written as Ofloxacin and Tinidazole?

A: The name Ofloxacin and Tinidazole refers to the active pharmaceutical ingredients that the medicine contains. Oflox-Tz is one of several trade names used by manufacturers to market the Fixed-Dose Combination (FDC) that contains these two distinct, active components.

Q: Is Oflox-Tz safe for older adults (seniors)?

A: Official safety statements describe the use of this medicine in older adults (over 60 years) as subject to special caution or restricted use. This population has a documented increased risk of tendon disorders associated with the Ofloxacin component of the drug.

Q: Does Oflox-Tz cause sleepiness or dizziness?

A: Official regulatory documents describe dizziness as a common adverse reaction associated with the treatment, primarily from the Tinidazole component. Other Central Nervous System (CNS) effects like confusion have also been documented, but sleepiness is not listed as a common effect.

Q: Is Oflox-Tz the same as just taking Ofloxacin?

A: No. Oflox-Tz is a Fixed-Dose Combination (FDC) that contains two distinct active ingredients: Ofloxacin and Tinidazole. Taking Ofloxacin alone would mean you would only receive the Ofloxacin component, which would not provide the dual antimicrobial coverage intended by the combination.

Q: Can Oflox-Tz affect birth control pills?

A: Consensus from authoritative health bodies indicates that the components of Oflox-Tz, which are from the quinolone and nitroimidazole classes, are generally not known to reduce the effectiveness of common hormonal contraceptives (birth control pills). The use of all medications, including hormonal contraceptives, is typically reviewed by a health professional before starting treatment.

Q: Can Oflox-Tz be taken on an empty stomach?

A: Official administration guidelines stipulate that the oral dose is to be taken during or immediately after a meal. This is the required condition described in the official prescribing information.

Q: Does Oflox-Tz make you more sensitive to the sun?

A: Official regulatory documents list photosensitivity as a rare adverse reaction associated with the medicine. This describes an increased tendency for the skin to react to sunlight, which may appear as a severe sunburn or rash in sun-exposed areas.

Q: How long does the effect of Oflox-Tz stay in the body after I stop taking it?

A: The speed at which the medicine is eliminated is described by the half-life of each component. The Ofloxacin component has an elimination half-life typically between 5.7 and 7.0 hours. The Tinidazole component decreases more slowly. Official data indicates that most of the medicine is eliminated from the system within several days after the last dose.

Q: What is the connection between Oflox-Tz and anxiety or mood changes?

A: Official regulatory documents note that the Ofloxacin component has been associated with Central Nervous System (CNS) effects. Rare reactions documented include confusion, and in some regulatory texts, the potential for mood changes or psychiatric reactions such as anxiety has been noted.

Q: Can Oflox-Tz cause changes in blood sugar levels?

A: Official regulatory documents describe that the Ofloxacin component, a fluoroquinolone, has the potential to cause changes in blood glucose regulation. This may result in either very low blood sugar (hypoglycemia) or, less commonly, very high blood sugar (hyperglycemia).

Q: Is Oflox-Tz associated with changes in heart rhythm?

A: Official safety statements note a formal limitation for patients with a history of QTc interval prolongation. This is a documented electrical change in the heart associated with the Ofloxacin component that may lead to changes in heart rhythm.

Q: Why is it common for Oflox-Tz to be prescribed for a week?

A: The total duration of treatment is determined by the site, type, and severity of the diagnosed infection. However, official regulatory documents detailing use for the Ofloxacin component show that many standard treatment courses described in labeling are typically set for lengths of 7 to 10 days.

Q: Is there a generic version of Oflox-Tz?

A: Yes. The two active ingredients, Ofloxacin and Tinidazole, are not exclusive. The existence of multiple brands with the identical composition (Fixed-Dose Combination) indicates that generic versions of the medicine are generally available.

How should Oflox-Tz be stored and disposed of?

Official Storage and Disposal Instructions

Official regulatory documents detail specific conditions required to maintain the stability and safety of Oflox-Tz (Ofloxacin and Ornidazole) tablets.

Storage and Handling

Condition	Requirement
Temperature	Store below 30 C (86°F).
Protection	Keep protected from light and moisture.
Container	Store in the original container or pack, tightly closed.
Safety	Keep the medicine out of the sight and reach of children.

Disposal Rules

Do not dispose of this medicine in household waste or wastewater, as directed by official labeling to help protect the environment. Ensure the unused medicine is not consumed by pets or other people. Consult your pharmacist for instructions on how to properly and safely dispose of Oflox-Tz when it is no longer required, and do not use the medicine past its labeled expiry date.

Oflox-Tz